Vitamin B6 for mastalgia: what the clinical trial found

What the 2016 trial tested

The study investigated whether pyridoxine, or vitamin B6, reduced mastalgia compared with placebo. Researchers recruited 126 patients from Amir-al-Momenin and Kowsar hospitals in Semnan, Iran.

Participants were randomly assigned to receive either vitamin B6 or placebo during a two-month study. Daily breast-pain charts tracked symptom intensity and days with severe pain.

The double-blind design helped limit expectation-related bias, an important consideration because breast pain can fluctuate naturally and respond to reassurance.

What the investigators reported

Mean pain scores and severe-pain frequency declined significantly during the trial. Improvement occurred in both the vitamin B6 and placebo groups.

Both groups also experienced reduced pain during the first five days. Investigators suggested reassurance might explain some early improvement, although this mechanism was not directly measured.

No adverse effects were reported during the study. However, the short observation period cannot establish the safety of prolonged high-dose supplementation. The authors concluded that vitamin B6 was effective, but improvement in both groups complicates that interpretation.

Trial design at a glance

Why the placebo response matters

Mastalgia can fluctuate with menstrual cycles, stress and time. Reassurance and expectations may also influence how patients experience symptoms.

Because both groups improved, the reduction observed among vitamin B6 recipients cannot independently demonstrate treatment effectiveness.

The critical comparison is whether vitamin B6 produces greater improvement than placebo. The reported findings do not establish a reliable additional benefit, and the study abstract does not provide a numerical between-group effect estimate with a confidence interval.

Improvement during treatment does not necessarily demonstrate that the treatment caused the improvement.

How later evidence changes the interpretation

A 2025 systematic review and meta-analysis examined three placebo-controlled studies of vitamin B6 for mastalgia.

The pooled analysis found no statistically significant improvement in pain intensity compared with placebo (SMD −3.57; 95% CI −9.15 to 2.01). Evidence certainty was rated very low because of methodological limitations, imprecision and substantial heterogeneity.

Another randomized trial compared vitamins B6 and E in 80 patients with cyclic mastalgia. Pain decreased in both groups, but the absence of a placebo arm prevented conclusions about vitamin B6's specific effectiveness.

Broader mastalgia reviews emphasize clinical assessment, conservative management and established symptom-relief options rather than vitamin supplementation as a proven first-line treatment.

What current evidence means for treatment decisions

Current research does not establish vitamin B6 as an effective treatment for mastalgia. However, very low-certainty evidence indicates uncertainty, not definitive proof that supplementation has no effect.

Breast pain may resolve or fluctuate without specific treatment. Clinical assessment considers whether symptoms are cyclical, focal, persistent or accompanied by concerning breast changes.

Conservative management is commonly appropriate when examination findings are reassuring. Persistent or severe symptoms may require further assessment and individualized treatment.

Safety also matters. The 2016 study investigated a high-dose regimen exceeding current general adult upper intake limits. The U.S. National Institutes of Health lists an upper limit of 100 mg/day, while the European Food Safety Authority established a lower limit of 12 mg/day in 2023.

Frequently asked questions